Measurable Residual Disease in Leukemia: Improving Qualification through MRDworst case
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal——Leukemia（11.4）. The title of the study is "Have we been qualifying measurable residual disease correctly?". The comparative analysis between MRDworst case and MRDconventional methodologies reveals a clear advantage in favor of the former, particularly in its capacity to enhance the accuracy of relapse risk prediction in leukemia patients.